PharmaPoint: HIV - France Drug Forecast and Market Analysis to 2022
Jan 31, 2013 - GlobalData - 147 pages
Abstract Table of Contents Request Details Related
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
3.2.1 Primary or Acute Infection
3.2.2 Chronic Infection
3.2.3 Advanced Infection/AIDS
4 Disease Management
4.1 Treatment Overview
4.2 France
4.2.1 Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Atripla (efavirenz/emtricitabine/tenofovir)
5.3.2 Complera (emtricitabine/tenofovir/rilpivirine)
5.3.3 Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine)
5.3.4 Truvada (tenofovir disoproxil fumarate/emtricitabine)
5.3.5 Epzicom (abacavir/lamivudine)
5.3.6 Kaletra (lopinavir/ritonavir)
5.3.7 Reyataz (atazanavir)
5.3.8 Prezista (darunavir)
5.3.9 Norvir (ritonavir)
5.3.10 Isentress (raltegravir)
5.3.11 Entry inhibitors
6 Opportunity and Unmet Need
6.1 Overview
6.1.1 Simplified regimens and dosing frequency
6.1.2 Side effects and toxicities
6.1.3 Drug resistance
6.1.4 Prophylaxis
6.1.5 Lack of functional cure
6.1.6 Patient awareness
6.1.7 Treatment availability
6.1.8 Treatment affordability
6.2 Unmet Needs Gap Analysis
6.3 Opportunities
6.3.1 Development of treatments to counter drug resistance
6.3.2 Collaborations to develop newer STRs
6.3.3 Development of new injectable formulations
6.3.4 Development of new prophylactics
6.3.5 Development of drugs that use a novel mechanism of action
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Cobicistat
7.2.2 Elvitegravir
7.2.3 Dolutegravir
7.2.4 572-Trii
7.2.5 Quad 2
8 Market Outlook
8.1 France
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 HIV Prevalence
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.5.1 Survery of Prescribing Physicians
9.6 About the Authors
9.6.1 Authors
9.6.2 Global Head of Healthcare
9.7 About GlobalData
9.8 Contact Us
9.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms HIV
Table 2: Treatment Guidelines for HIV
Table 3: Most Prescribed Drugs for HIV by Class in the France Market, 2012
Table 4: Leading Treatments for HIV, 2012
Table 5: Product Profile - Atripla
Table 6: Atripla SWOT Analysis, 2012
Table 7: Product Profile - Complera
Table 8: Complera SWOT Analysis, 2012
Table 9: Product Profile - Stribild
Table 10: Stribild SWOT Analysis, 2012
Table 11: Product Profile - Truvada
Table 12: Truvada SWOT Analysis, 2012
Table 13: Product Profile - Epzicom
Table 14: Epzicom SWOT Analysis, 2012
Table 15: Product Profile - Kaletra
Table 16: Kaletra SWOT Analysis, 2012
Table 17: Product Profile - Reyataz
Table 18: Reyataz SWOT Analysis, 2012
Table 19: Product Profile - Prezista
Table 20: Prezista SWOT Analysis, 2012
Table 21: Product Profile - Norvir
Table 22: Norvir SWOT Analysis, 2012
Table 23: Product Profile - Isentress
Table 24: Percent of Patients with HIV RNA Levels<50 Copies/mL from SMARTMRK Study
Table 25: Isentress SWOT Analysis, 2012
Table 26: Summary of Minor Therapeutic Classes, 2012
Table 27: Overall Unmet Needs - Current Level of Attainment
Table 28: Clinical Unmet Needs - Gap Analysis, 2012
Table 29: HIV - Promising Drugs in Clinical Development, 2012
Table 30: Comparison of Therapeutic Classes in Development for HIV, 2012
Table 31: Product Profile - Cobicistat
Table 32: Cobicistat SWOT Analysis, 2012
Table 33: Product Profile - Elvitegravir
Table 34: Elvitegravir SWOT Analysis, 2012
Table 35: Product Profile - Dolutegravir
Table 36: Dolutegravir SWOT Analysis, 2012
Table 37: Product Profile - 572-Trii
Table 38: 572-Trii SWOT Analysis, 2012
Table 39: Product Profile - Quad 2
Table 40: Quad 2 SWOT Analysis, 2012
Table 41: Sales Forecasts ($m) for HIV in France, 2012-2022
Table 42: Key Events Impacting Sales for HIV in France, 2012-2022
Table 43: France HIV Therapeutics Market - Drivers and Barriers, 2012-2022
Table 44: Key Launch Dates
Table 45: Key Patent Expiries
Table 46: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: HIV Lifecycle
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2012-2022
Figure 3: Sales for HIV Therapeutics in France by Drug Class, 2012-2022

Order This Report


EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.